Heterocyclic compounds having inhibitory activity against hiv integrase
    2.
    发明申请
    Heterocyclic compounds having inhibitory activity against hiv integrase 有权
    对hiv整合酶具有抑制活性的杂环化合物

    公开(公告)号:US20060128669A1

    公开(公告)日:2006-06-15

    申请号:US10524281

    申请日:2003-08-11

    摘要: A heterocyclic compound of the formula (I): wherein B1 is —C(R2)═ or —N═; R1′ is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is —C(—Y)═C(—RA)—C(—R3)═C(—R4)—, etc. wherein Y is OH, etc.; RA is —COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

    摘要翻译: 式(I)的杂环化合物:其中B 1是-C(R 2) - 或-N-; R 1是H等; R 1和R 2之一是-Z 1 -Z 2 -Z 3, 其中Z 1和Z 3独立地是单键,任选取代的亚烷基等;其中Z 1和Z 3独立地是单键,任选取代的亚烷基等; Z 2是单键,任选取代的亚烷基等; R 5是任选取代的芳基,任选取代的杂芳基等,R 1和R 2中的另一个是H; -C(-Y)-C(-R A) - C(-R 3) - C( - ) - R 4) - 等,其中Y是OH等; R A是其中R 7是OH的-COR 7,等等; R 3和R 4之一是羧基等,R 1和R 2中的另一个是 是具有抗病毒活性的H,等等,其前体药物,其药学上可接受的盐及其溶剂合物,更具体地,涉及针对HIV整合酶的抑制活性,以及​​含有该抑制活性的药物组合物,特别是抗HIV药物。

    Heterocyclic compounds having inhibitory activity against HIV integrase
    4.
    发明申请
    Heterocyclic compounds having inhibitory activity against HIV integrase 审中-公开
    对HIV整合酶具有抑制活性的杂环化合物

    公开(公告)号:US20090118233A1

    公开(公告)日:2009-05-07

    申请号:US12071807

    申请日:2008-02-26

    摘要: A heterocyclic compound of the formula (I): wherein B1 is —C(R2)═ or —N═; R1′ is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is —C(—Y)═C(—RA)—C(—R3)═C(—R4)—, etc. wherein Y is OH, etc.; RA is —COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

    摘要翻译: 式(I)的杂环化合物:其中B1为-C(R2) - 或-N-; R1'为H等; R1和R2之一是-Z1-Z2-Z3-R5,其中Z1和Z3独立地是单键,任选取代的亚烷基等; Z2是单键,任选取代的亚烷基等; R5是任选取代的芳基,任选取代的杂芳基等,R 1和R 2中的另一个是H; -A1-是-C(-Y)-C(-RA)-C(-R 3)-C(-R 4) - 等,其中Y是OH等; RA是-COR 7,其中R 7是OH等; R 3和R 4之一为羧基等,R 1和R 2中的另一个为H,其前体药物,其药学上可接受的盐及其溶剂化物,具有抗病毒活性,更具体地, HIV整合酶,以及包含其的药物组合物,特别是抗HIV药物。

    Heterocyclic compounds having inhibitory activity against HIV integrase
    5.
    发明授权
    Heterocyclic compounds having inhibitory activity against HIV integrase 有权
    对HIV整合酶具有抑制活性的杂环化合物

    公开(公告)号:US07358249B2

    公开(公告)日:2008-04-15

    申请号:US10524281

    申请日:2003-08-11

    摘要: A heterocyclic compound of the formula (I): wherein B1 is —C(R2)═ or —N═; R1′ is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is —C(—Y)═C(—RA)—C(—R3)═C(—R4)—, etc. wherein Y is OH, etc.; RA is —COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

    摘要翻译: 式(I)的杂环化合物:其中B 1是-C(R 2) - 或-N-; R 1是H等; R 1和R 2之一是-Z 1 -Z 2 -Z 3, 其中Z 1和Z 3独立地是单键,任选取代的亚烷基等;其中Z 1和Z 3独立地是单键,任选取代的亚烷基等; Z 2是单键,任选取代的亚烷基等; R 5是任选取代的芳基,任选取代的杂芳基等,R 1和R 2中的另一个是H; -C(-Y)-C(-R A) - C(-R 3) - C( - ) - R 4) - 等,其中Y是OH等; R A是其中R 7是OH的-COR 7,等等; R 3和R 4之一是羧基等,R 1和R 2中的另一个是 是具有抗病毒活性的H,等等,其前体药物,其药学上可接受的盐及其溶剂合物,更具体地,涉及针对HIV整合酶的抑制活性,以及​​含有其的药物组合物,特别是抗HIV药物。

    Heterocyclic compounds having inhibitory activity against HIV integrase
    6.
    发明申请
    Heterocyclic compounds having inhibitory activity against HIV integrase 审中-公开
    对HIV整合酶具有抑制活性的杂环化合物

    公开(公告)号:US20060247212A1

    公开(公告)日:2006-11-02

    申请号:US11478218

    申请日:2006-06-30

    摘要: A heterocyclic compound of the formula (I): wherein B1 is —C(R2)═ or —N═; R1′ is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R1 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is —C(—Y)═C(—RA)—C(—R3)═C(—R4)—, etc. wherein Y is OH, etc.; RA is —COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

    摘要翻译: 式(I)的杂环化合物:其中B 1是-C(R 2) - 或-N-; R 1是H等; R 1和R 2之一是-Z 1 -Z 2 -Z 3, 其中Z 1和Z 3独立地是单键,任选取代的亚烷基等;其中Z 1和Z 3独立地是单键,任选取代的亚烷基等; Z 2是单键,任选取代的亚烷基等; R 1是任选取代的芳基,任选取代的杂芳基等,R 1和R 2中的另一个是H; -C(-Y)-C(-R A) - C(-R 3) - C( - ) - R 4) - 等,其中Y是OH等; R A是其中R 7是OH的-COR 7,等等; R 3和R 4之一是羧基等,R 1和R 2中的另一个是 是具有抗病毒活性的H,等等,其前体药物,其药学上可接受的盐及其溶剂合物,更具体地,涉及针对HIV整合酶的抑制活性,以及​​含有其的药物组合物,特别是抗HIV药物。

    TRPV1 antagonists including dihydroxy substituent and uses thereof
    7.
    发明授权
    TRPV1 antagonists including dihydroxy substituent and uses thereof 有权
    TRPV1拮抗剂包括二羟基取代基及其用途

    公开(公告)号:US09273043B2

    公开(公告)日:2016-03-01

    申请号:US14127903

    申请日:2012-06-21

    摘要: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.

    摘要翻译: 本公开涉及式(I)化合物及其药学上可接受的衍生物,其中R 1,R 4,R 8,R 9和m如本文所定义,包含有效量的式(I)化合物或其药学上可接受的衍生物 以及用于治疗或预防与骨关节炎,骨关节炎,UI,溃疡,IBD和IBS相关的疼痛,疼痛,溃疡,IBD和IBS等症状的治疗或预防方法,其包括向有需要的动物施用有效量的式(I)化合物, 或其药学上可接受的衍生物。

    TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF
    9.
    发明申请
    TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF 有权
    TRPV1拮抗剂包括二氢替代物及其用途

    公开(公告)号:US20140329829A1

    公开(公告)日:2014-11-06

    申请号:US14127903

    申请日:2012-06-21

    IPC分类号: C07D417/14

    摘要: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.

    摘要翻译: 本公开涉及式(I)化合物及其药学上可接受的衍生物,其中R 1,R 4,R 8,R 9和m如本文所定义,包含有效量的式(I)化合物或其药学上可接受的衍生物 以及用于治疗或预防与骨关节炎,骨关节炎,UI,溃疡,IBD和IBS相关的疼痛,疼痛,溃疡,IBD和IBS等症状的治疗或预防方法,其包括向有需要的动物施用有效量的式(I)化合物, 或其药学上可接受的衍生物。